Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Proliferative ischemic retinopathies lead to a formation of abnormal vessels on the iris
surface induced by an increased level of vascular endothelial growth factor (VEGF). In
progressive stages fibrovascular membranes occlude the anterior chamber angle which inhibits
aqueous outflow resulting in neovascular glaucoma. The increased intraocular pressure is
often difficult to control and frequently results in loss of vision.
The aim of this study is to analyze the short- and long-term outcome after adjuvant
intraocular Ranibizumab application in patients with neovascular glaucoma and rubeosis and to
analyze the role of ranibizumab within a holistic treatment regime.